title: Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer.
authors.forename: J M
authors.initials: JM
authors.lastname: Bennett
authors.forename: A B
authors.initials: AB
authors.lastname: Troxel
authors.forename: R
authors.initials: R
authors.lastname: Gelman
authors.forename: G
authors.initials: G
authors.lastname: Falkson
authors.forename: M D
authors.initials: MD
authors.lastname: Coccia-Portugal
authors.forename: R
authors.initials: R
authors.lastname: Dreicer
authors.forename: D C
authors.initials: DC
authors.lastname: Tormey
authors.forename: D
authors.initials: D
authors.lastname: Rushing
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced*; D008875:Middle Aged; D008936:Mitolactol / Q000009:adverse effects* / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D012307:Risk Factors
chemical_list: D008936:Mitolactol